Integral control of risk factors in patients of high and very high cardiovascular risk in Spain. CIFARC project;Control integral de los factores de riesgo en pacientes de alto y muy alto riesgo cardiovascular en España. Estudio CIFARC

Medicina Clinica

Volumn 124, Issue 2, 2005, Pages 44-49

  De La Peña Fernández, Andrés ^a   Suárez Fernández, Carmen ^b   Cuende Melero, Ignacio ^c   Muñoz Rodríguez, Manuel ^d   Garré Cánovas, José ^e   Camafort Babkowski, Miguel ^f   Roca Villanueva, Bernardino ^g   Alcalá Pedraja, José ^h  

^a HOSPITAL SON LLÀTZER   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c Hospital Provincial San Telmo   (Spain)

^d HOSPITAL DE LEÓN   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

^f Hospital Comarcal Mora d'Ebre   (Spain)

^g HOSPITAL GENERAL DE CASTELLÓN   (Spain)

^h Hospital Valle de los Pedroches   (Spain)

Author keywords

High cardiovascular risk; Integral control cardiovascular risk factors

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT;

ADULT; AGED; AMBULATORY CARE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES CONTROL; DIABETES MELLITUS; DISEASE PREDISPOSITION; DYSLIPIDEMIA; FEMALE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; PRACTICE GUIDELINE; PROTEINURIA; RISK ASSESSMENT; RISK FACTOR; SPAIN; TOBACCO; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION;

EID: 13444287804     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13070450     Document Type: Article

References (22)

1. Murray CJL, López A. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet. 1997; 347:1498-504.
2. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. J Hypertens. 1998;16:1407-14.
3. American Diabetes Association. Clinical practice recommendations 1997. Diabetes Care. 1997; 20 Suppl 1:1-70.
4. Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention: scientific review. JAMA. 2002;288:1388-95.
5. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-13.
6. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
7. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet. 2001;357:995-1001.
8. De Velasco JA, Cosín J, López-Sendón JL, De Teresa E, De Oya M, Sellers G. Nuevos datos en prevención secundaria del infarto de miocardio en España. Resultados del estudio PREVESE II. Rev Esp Cardiol. 2002;55:801-9.
9. Filippi A, Bignamini AA, Sessa E, Samani F, Mazzaglia G. Secondary prevention of stroke in Italy: a cross-sectional survey in family practice Stroke. 2003;34:1010-4.
10. Redfern J, McKevitt C, Rudd AG, Wolfe CD. Health care follow-up after stroke: opportunities for secondary prevention. Fam Pract. 2002;19:378-82.
11. Sappok T, Faulstich A, Stuckert E, Kruck H, Marx P, Koennecke HC. Compliance with secondary prevention of ischemic stroke: a prospective evaluation. Stroke. 2001;32:1884-9.
12. EUROASPIRE II. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 2001;22:554-72.
13. World Health Organization/International Society of Hypertension. Guidelines for the management of hypertension. Guidelines Subcommittee. J Hypertens. 1999;17:151-83.
14. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285: 2486-97.
15. De la Calle H, Costa A, Díez-Espino J, Franch J, Goday A. Evaluación de la cumplimentación de los objetivos del síndrome metabólico en pacientes ambulatorios con diabetes mellitus tipo 2 en España. El estudio TranSTAR. Med Clin (Barc). 2003;120:446-50.
16. De Velasco JA, Cosín J, López Sendón JL, De Teresa E, De Oya M, Carrasco JL, et al. Prevención secundaria en el infarto de miocardio en España. El estudio PREVESE. Rev Esp Cardiol. 1997;50:406-15.
17. Martin Escudero JC, Simal Blanco F, Carretero Ares JL, Bellido Casado J, Arzúa Mouronte D, Mena Martín F, et al. Prevalencia, grado de detección, tratamiento y control de la hipertensión arterial en la población general. Estudio Hortega. Hipertensión. 2003;20:148-54.
18. Gómez Belda A, Rodilla E, Albert A, García L, González C, Pascual JM. Uso clínico de las estatinas y objetivos terapéuticos en relación con el riesgo cardiovascular. Med Clin (Barc). 2003; 121:527-31.
19. Barrios V, Ruilope LM, Llisterrio JL, Álvarez-Sala L, Esmatjes E, Franch J, et al, en representación del Grupo PREVENCAT. Prevención de la Enfermedad Cardiovascular. Actuación terapéutica actual en atención primaria. Estudio PREVENCAT. Actas del XXIX Congreso de la Sociedad Española de Cardiologia; octubre 2003.
20. Barrios V, Navarro-Cid J, Calderón A, Bosch I, Ylla-Catalá A, Campuzano R, et al. Comparación del riesgo cardiovascular de la población hipertensa en atención primaria con el de atención especializada. Estudio CONTROLRISC. Hipertension. 2002;19:1-34.
21. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-58.
22. Serrano RM, Ascaso Gimjlio JF, Blázquez FE, Cabezas CJ, Carmena RR, Escobar JF, et al. Resistencia a la insulina y su implicación en multiples factores de riesgo asociados diabetes tipo 2. Med Clin (Barc). 2002;119:458-63.